On this page
1q21.1 deletion syndrome
This rare condition occurs when a specific region on chromosome 1 is missing, affecting development and causing variable features including learning difficulties, developmental delays, and certain physical characteristics. The severity and specific features differ considerably between affected individuals.
Overview
1q21.1 deletion syndrome arises when a small segment of chromosome 1, specifically at position 1q21.1, is absent. This missing section typically contains multiple genes that contribute to normal development and body function. The condition is recognised as a copy number variant, meaning affected individuals have one less copy of this chromosomal region than expected.
Because the deleted region encompasses several genes working together, the clinical picture varies widely between individuals. Some people with this deletion experience significant developmental challenges, whilst others have much milder features or may go undiagnosed into adulthood. The condition is rare, though exact prevalence figures remain uncertain as milder cases may not come to clinical attention. Recognition has increased with widespread use of chromosomal microarray testing in clinical genetics services.
Symptoms & clinical features
Developmental delay represents one of the most common features, with many affected children reaching milestones such as walking and talking later than expected. Learning difficulties occur frequently, ranging from mild challenges requiring educational support to more significant intellectual disability. Speech and language development often lags behind other skills, and some individuals benefit from speech therapy.
Physical features may include subtle facial characteristics, though these are not always distinctive enough to suggest the diagnosis on appearance alone. Head size can be smaller than average (microcephaly) in some cases. Growth patterns vary, with some children being shorter than their peers. Additional features that may occur include heart defects, particularly affecting the structure of the heart, seizures in a proportion of affected individuals, and skeletal differences such as minor hand or foot anomalies. Behavioural challenges and features overlapping with autism spectrum conditions have been reported in some cases.
Video: Genetics 101
Affected organs
The brain is the most consistently affected organ system, with developmental differences accounting for the learning and behavioural features. Brain imaging occasionally reveals structural variations, though many individuals have normal scans.
The heart may be affected in a subset of cases, with congenital heart defects occurring more frequently than in the general population. The skeletal system can show minor variations, and growth regulation may be impacted. Because multiple genes are deleted simultaneously, the range of potentially affected systems is broad, contributing to the variable clinical picture observed across different families.
Risks & severity
Severity spans a remarkably wide spectrum. Some individuals require substantial support throughout life due to significant learning disability and medical complications, whilst others function independently with only mild learning difficulties or behavioural traits. This variability exists even within the same family, making it challenging to predict outcomes when the deletion is identified prenatally or in early childhood.
Congenital heart defects, when present, may require surgical intervention in infancy or childhood. Seizures affect a minority of individuals and typically respond to standard anticonvulsant management. Developmental progress continues throughout childhood, and many affected individuals acquire new skills with appropriate educational support. Long-term outcomes depend largely on the severity of learning difficulties and presence of additional medical features, with some adults living independently and others requiring ongoing care.
Genetic causes
The deletion arises from loss of genetic material at chromosome band 1q21.1, a region known to contain multiple genes contributing to normal development. This occurs as a spontaneous event during formation of egg or sperm cells, or very early in embryonic development. The deleted segment varies in size between individuals, which may partly explain the clinical variability.
The specific genes within this region that contribute to the clinical features are still being researched. Because multiple genes are lost simultaneously, the condition represents a contiguous gene deletion syndrome, where the combined effect of losing several genes produces the observed features. The normal function of these genes relates to brain development, growth regulation, and formation of various body structures during embryonic development.
Inheritance pattern
Most cases occur as new (de novo) deletions, meaning the chromosomal change arose spontaneously and was not inherited from either parent. Parents of an affected child typically have normal chromosomes and face a low recurrence risk in future pregnancies.
However, once the deletion is present in an individual, it can be passed to children. Each child of a person carrying the deletion has a 50% chance of inheriting it. Because of the variable expression, an affected parent might have mild features whilst their child could be more significantly affected, or vice versa. Rarely, a parent carries the deletion in some but not all cells (mosaicism), which can complicate genetic counselling. Family testing is typically offered when a deletion is identified in a child.
Diagnosis & testing
Diagnosis is confirmed through chromosomal microarray analysis, a genetic test that detects deletions and duplications across all chromosomes. This test has become standard practice in the NHS when investigating unexplained developmental delay, learning disability, or autism spectrum conditions. It can identify the 1q21.1 deletion even when clinical features are not specific enough to suggest this particular diagnosis.
Clinical geneticists typically coordinate the diagnostic process following referral from paediatricians, community child health teams, or neurodevelopmental services. The test may be performed prenatally if chromosomal microarray is undertaken during pregnancy, sometimes identifying the deletion before birth when investigation is done for other reasons. Genetic counselling forms an essential part of the diagnostic pathway, helping families understand test results and implications for the affected individual and relatives.
Management & lifestyle
Management focuses on addressing individual features and supporting development. Children benefit from early developmental input, including physiotherapy, occupational therapy, and speech and language therapy tailored to their specific needs. Educational support plans help maximise learning potential within mainstream or specialist educational settings.
Medical surveillance includes cardiac assessment, typically with echocardiography, to identify any structural heart problems requiring monitoring or treatment. Growth is tracked, and any seizures are managed by paediatric neurology services. Regular developmental reviews allow care to be adjusted as the child progresses. Behavioural support and mental health input may be helpful when challenges arise.
Families often benefit from connecting with support organisations for rare chromosomal conditions. Genetic counselling remains available to discuss family planning and testing options for relatives. Transition planning helps young people move from paediatric to adult services where ongoing support is needed.
UK care pathway
Within the NHS Genomic Medicine Service, children with unexplained developmental delay or learning disability are typically referred to clinical genetics services, where chromosomal microarray testing can identify the deletion. The condition would be managed through paediatric services coordinating various therapies and medical input as needed.
Genetic counsellors provide families with detailed information about the condition, recurrence risks, and testing options for family members. Adult genetics services may see parents requesting testing after a child is diagnosed, or adults identified with milder features seeking information about risks to their own children. Access to genetic counselling supports informed decision-making about family planning and helps families understand the variable nature of the condition.
Frequently asked questions
Will my child with 1q21.1 deletion syndrome be able to live independently as an adult?
This depends on the severity of learning difficulties and any medical complications. Some adults with this deletion live independently with minimal support, whilst others require ongoing assistance. Developmental progress continues throughout childhood, making it difficult to predict adult outcomes when children are young.
If one of my children has this deletion, what is the chance another child would have it?
If neither parent carries the deletion, the recurrence risk is very low (typically less than 1%). If a parent is found to carry the deletion, each pregnancy has a 50% chance of inheriting it, though severity can vary widely even within families.
Could I have the deletion without knowing it?
Yes, some adults carry the deletion with very mild features that never prompted medical investigation. If your child is diagnosed, your clinical genetics team will typically offer parental testing to clarify recurrence risks and provide appropriate genetic counselling.
What support is available for families affected by rare chromosomal conditions?
The NHS provides access to clinical genetics services, genetic counsellors, and developmental support teams. Organisations such as Unique (supporting families with rare chromosome and gene disorders) offer information and family contact networks. Educational support is available through local authority special educational needs services.
References
- Wang F, Peng H, Lou G. Prenatal ultrasound phenotype of fetuses with recurrent 1q21.1 deletion and duplication syndrome. Frontiers in pediatrics. 2024. PMID: 39840309
- Pang H, Yu X, Kim YM. Disorders Associated With Diverse, Recurrent Deletions and Duplications at 1q21.1. Frontiers in genetics. 2020. PMID: 32655619
- Upadhyai P, Amiri EF, Guleria VS. Recurrent 1q21.1 deletion syndrome: report on variable expression, nonpenetrance and review of literature. Clinical dysmorphology. 2020. PMID: 32459673
- Alzarka B, Usala R, Whitehead MT. Hyponatremia: An Unusual Presentation in a Neonate With Chromosome 1q21.1 Deletion Syndrome. Frontiers in pediatrics. 2018. PMID: 30364227
- Nagy S, Maurer GW, Hentze JL. AMPK signaling linked to the schizophrenia-associated 1q21.1 deletion is required for neuronal and sleep maintenance. PLoS genetics. 2018. PMID: 30566533
- Gamba BF, Zechi-Ceide RM, Kokitsu-Nakata NM. Interstitial 1q21.1 Microdeletion Is Associated with Severe Skeletal Anomalies, Dysmorphic Face and Moderate Intellectual Disability. Molecular syndromology. 2016. PMID: 27920638
- Papoulidis I, Oikonomidou E, Orru S. Prenatal detection of TAR syndrome in a fetus with compound inheritance of an RBM8A SNP and a 334‑kb deletion: a case report. Molecular medicine reports. 2014. PMID: 24220582